

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
16 October 2003 (16.10.2003)


PCT

(10) International Publication Number  
WO 03/085131 A2

- (51) International Patent Classification<sup>7</sup>: C12Q 1/68 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/EP03/03626
- (22) International Filing Date: 8 April 2003 (08.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
02007820.0 8 April 2002 (08.04.2002) EP  
60/370,214 8 April 2002 (08.04.2002) US
- (71) Applicant (*for all designated States except US*): EVOTEC NEUROSCIENCES GMBH [DE/DE]; Schnackenburgallee 114, 22525 Hamburg (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): VON DER KAMMER, Heinz [DE/DE]; Verbindungsstr. 6d, 22607 Hamburg (DE). POHLNER, Johannes [DE/DE]; Quittenweg 11, 22175 Hamburg (DE).
- (74) Agents: MEYERS, Hans-Wilhelm et al.; Postfach 10 22 41, 50462 Köln (DE).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: DIAGNOSTIC AND THERAPEUTIC USE OF VAULT POLYNUCLEOTIDES AND PROTEINS FOR NEURODEGENERATIVE DISEASES

**Fig. 2: Identification of differentially expressed Alzheimer's disease genes in a fluorescence differential display screen**



(57) Abstract: The present invention discloses the differential expression of the minor vault protein ADPRTL gene in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating Alzheimer's disease in a subject, or for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using a gene coding for a vault protein, in particular the gene coding for the minor vault protein ADPRTL1. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

BEST AVAILABLE COPY

**DIAGNOSTIC AND THERAPEUTIC USE OF VAULT POLYNUCLEOTIDES AND  
PROTEINS FOR NEURODEGENERATIVE DISEASES**

The present invention relates to methods of diagnosing, prognosticating and monitoring the progression of neurodegenerative diseases in a subject. Furthermore, methods of therapy control and screening for modulating agents of neurodegenerative diseases are provided. The invention also discloses pharmaceutical compositions, kits, and recombinant animal models.

Neurodegenerative diseases, in particular Alzheimer's disease (AD), have a strongly debilitating impact on a patient's life. Furthermore, these diseases constitute an enormous health, social, and economic burden. AD is the most common neurodegenerative disease, accounting for about 70% of all dementia cases, and it is probably the most devastating age-related neurodegenerative condition affecting about 10% of the population over 65 years of age and up to 45% over age 85 (for a recent review see Vickers et al., *Progress in Neurobiology* 2000, 60: 139-165). Presently, this amounts to an estimated 12 million cases in the US, Europe, and Japan. This situation will inevitably worsen with the demographic increase in the number of old people ("aging of the baby boomers") in developed countries. The neuropathological hallmarks that occur in the brains of individuals with AD are senile plaques, composed of amyloid- $\beta$  protein, and profound cytoskeletal changes coinciding with the appearance of abnormal filamentous structures and the formation of neurofibrillary tangles.

The amyloid- $\beta$  ( $A\beta$ ) protein evolves from the cleavage of the amyloid precursor protein (APP) by different kinds of proteases. The cleavage by the  $\beta/\gamma$ -secretase leads to the formation of  $A\beta$  peptides of different lengths, typically a short more soluble and slow aggregating peptide consisting of 40 amino acids and a longer 42 amino acid peptide, which rapidly aggregates outside the cells, forming the characteristic amyloid plaques (Selkoe, *Physiological Rev* 2001, 81: 741-66; Greenfield et al., *Frontiers Bioscience* 2000, 5: D72-83). Two types of plaques, diffuse plaques and neuritic plaques, can be detected in the brain of AD patients, the latter ones being the classical, most prevalent type. They are primarily found in the cerebral cortex and hippocampus. The neuritic plaques have a diameter of 50 $\mu$ m to 200 $\mu$ m and are composed of insoluble fibrillar amyloids, fragments of dead neurons, of microglia and astrocytes, and other components such as

neurotransmitters, apolipoprotein E, glycosaminoglycans,  $\alpha$ 1-antichymotrypsin and others. The generation of toxic A $\beta$  deposits in the brain starts very early in the course of AD, and it is discussed to be a key player for the subsequent destructive processes leading to AD pathology. The other pathological hallmarks of AD are neurofibrillary tangles (NFTs) and abnormal neurites, described as neuropil threads (Braak and Braak, *Acta Neuropathol* 1991, 82: 239-259). NFTs emerge inside neurons and consist of chemically altered tau, which forms paired helical filaments twisted around each other. Along the formation of NFTs, a loss of neurons can be observed. It is discussed that said neuron loss may be due to a damaged microtubule-associated transport system (Johnson and Jenkins, *J Alzheimers Dis* 1996, 1: 38-58; Johnson and Hartigan, *J Alzheimers Dis* 1999, 1: 329-351). The appearance of neurofibrillary tangles and their increasing number correlates well with the clinical severity of AD (Schmitt et al., *Neurology* 2000, 55: 370-376).

AD is a progressive disease that is associated with early deficits in memory formation and ultimately leads to the complete erosion of higher cognitive function. The cognitive disturbances include among other things memory impairment, aphasia, agnosia and the loss of executive functioning. A characteristic feature of the pathogenesis of AD is the selective vulnerability of particular brain regions and subpopulations of nerve cells to the degenerative process. Specifically, the temporal lobe region and the hippocampus are affected early and more severely during the progression of the disease. On the other hand, neurons within the frontal cortex, occipital cortex, and the cerebellum remain largely intact and are protected from neurodegeneration (Terry et al., *Annals of Neurology* 1981, 10: 184-92).

The age of onset of AD may vary within a range of 50 years, with early-onset AD occurring in people younger than 65 years of age, and late-onset of AD occurring in those older than 65 years. About 10% of all AD cases suffer from early-onset AD, with only 1-2% being familial, inherited cases.

Currently, there is no cure for AD, nor is there an effective treatment to halt the progression of AD or even to diagnose AD ante-mortem with high probability. Several risk factors have been identified that predispose an individual to develop AD, among them most prominently the epsilon 4 allele of the three different existing alleles (epsilon 2, 3, and 4) of the apolipoprotein E gene (ApoE) (Strittmatter et al., *Proc Natl Acad Sci USA* 1993, 90: 1977-81; Roses, *Ann NY Acad Sci* 1998, 855: 738-43). The polymorphic plasmaprotein ApoE plays a role in the intercellular cholesterol and phospholipid transport by binding low-density lipoprotein receptors,

and it seems to play a role in neurite growth and regeneration. Efforts to detect further susceptibility genes and disease-linked polymorphisms, lead to the assumption that specific regions and genes on human chromosomes 10 and 12 may be associated with late-onset AD (Myers et al., *Science* 2000, 290: 2304-5; Bertram et al., *Science* 2000, 290: 2303; Scott et al., *Am J Hum Genet* 2000, 66: 922-32).

Although there are rare examples of early-onset AD which have been attributed to genetic defects in the genes for amyloid precursor protein (APP) on chromosome 21, presenilin-1 on chromosome 14, and presenilin-2 on chromosome 1, the prevalent form of late-onset sporadic AD is of hitherto unknown etiologic origin. The mutations found to date account for only half of the familial AD cases, which is less than 2% of all AD patients. The late onset and complex pathogenesis of neurodegenerative disorders pose a formidable challenge to the development of therapeutic and diagnostic agents. It is crucial to expand the pool of potential drug targets and diagnostic markers. It is therefore an object of the present invention to provide insight into the pathogenesis of neurological diseases and to provide methods, materials, agents, compositions, and animal models which are suited inter alia for the diagnosis and development of a treatment of these diseases. This object has been solved by the features of the independent claims. The subclaims define preferred embodiments of the present invention.

Vaults are barrel-shaped ribonucleoprotein complexes of 13 Mega Dalton molecular weight. They are composed of three protein species and an untranslated RNA molecule called vault or vRNA. The three vault proteins are named major vault protein (or, alternatively, MVP, LRP, p100), minor vault protein TEP1 (p240), and minor vault protein ADPRTL1 (VPARP, PHP5, p193). The major vault protein is present in 96 copies per vault particle, and the minor vault proteins TEP1 and ADPRTL1 are found in 2 and 8 copies per particle, respectively (Kong et al., *RNA* 2000, 6: 890-900; Scheffer et al., *Curr. Opin. Oncol.* 2000, 12: 550-556). Vaults of nearly identical size and composition have been found in species as diverse as mammals, avians, amphibians, and the slime mold *Dictyostelium discoideum*. In spite of this evolutionary conserved and therefore apparently important function the exact cellular role of vaults is far from being understood. Several studies have implicated vaults in nucleocytoplasmic transport of different substrates including steroid hormone receptors and ribosomal particles (Scheffer et al., *Curr. Opin. Oncol.* 2000, 12: 550-556). Tissue distribution studies of vault components have shown higher levels of vaults in tissues that are chronically exposed to elevated

levels of xenobiotics, in metabolically active tissue and in macrophages. An up-regulation of vault expression during the differentiation and maturation of human monocyte-derived dendritic cells, known as xenobiotic scavenging cells, has been observed in vitro (Scheffer et al., *Curr. Opin. Oncol.* 2000, 12: 550-556). Collectively, this argues for a prominent role of vaults in detoxification of tissues (Kickhoefer et al., *J. Cell Biol.* 1999, 146: 917-928; Scheffer et al., *Curr. Opin. Oncol.* 2000, 12: 550-556). Of outstanding medical relevance was the finding that vaults are overexpressed in multidrug-resistant cancer cell lines and expression levels of vault components correlated with the extent of drug resistance, again arguing for a role in transport of xenobiotics and tissue detoxification (Schoeijers et al., *Cancer Res.* 2000, 60: 1104-1110; Siva et al., *Int. J. Cancer* 2001, 92: 195-202; Scheffer et al., *Curr. Opin. Oncol.* 2000, 12: 550-556). In fact, the major vault protein has also been coined LRP, which stands for lung resistance-related protein (Scheper et al., *Cancer Res.* 1993, 53: 1475-1479).

While the major vault protein is thought to play a more structural role in particle assembly, the minor vault proteins seem to play more active, enzymatic roles. The minor vault protein TEP1 is shared with so called telomerase complexes, other ribonucleoprotein complexes essential for the maintenance of the length of the chromosomal telomeres in dividing cells (Kickhoefer et al., *J. Biol. Chem.* 1999, 274: 32712-32717; Collins, *Curr. Opin. Cell Biol.* 2000, 12: 378-383). However, thus far it has not been demonstrated that vaults have telomerase activity (Kickhoefer et al., *J. Biol. Chem.* 1999, 274: 32712-32717). The other minor vault protein, ADPRTL1, also called p193, offers a number of interesting homologies to well known cellular factors: an amino-terminal BRCT domain shared with proteins active in DNA repair, a poly (ADP-ribose) polymerase domain that may hold a function in cellular differentiation, proliferation, tumor transformation, and recovery from DNA damage, an inter-alpha-trypsin inhibitor domain, a putative nuclear localization signal, and a carboxy-terminal domain for interaction with the major vault protein (Still et al., *Genomics* 1999, 62: 533-536; Kickhoefer et al., *J. Cell Biol.* 1999, 146: 917-928; Jean et al., *FEBS Lett.* 1999, 446: 6-8; Chiarugi, *Trends Pharmacol. Sci.* 2002, 23: 122-129). A patent application featuring purified human ADPRTL1/p193 nucleotide sequences, polypeptide sequences, and variants thereof, for the diagnosis and treatment of multidrug resistant cancer has been put forward (WO 99/62547). The nucleotide sequence of the gene coding for ADPRTL1 was initially determined by Still et al. (*Genomics* 1999, 62:533-536) and deposited in the GenBank database

with the accession number AF057160. The ADPRTL1 gene codes for a polypeptide of 1724 amino acids in length with a predicted molecular weight of 193 kDa.

It is primarily the combination of the BRCT domain with the poly(ADP-ribose) polymerase domain that fuels interest in ADPRTL1. It was found that ADPRTL1 poly(ADP-ribosyl)ates itself and the major vault protein at the expense of nicotinicamide adenine dinucleotide (Kickhoefer et al., *J. Cell Biol.* 1999, 146: 917-928). This activity resembles the enzymatic activity of a large family of poly(ADP-ribose) polymerases or PARPs (Johansson, *Genomics* 1999, 57: 442-445; Chiarugi, *Trends Pharmacol. Sci.* 2002, 23: 122-129). PARPs sense DNA damage and participate in DNA excision repair. Upon binding to DNA strand breaks, PARPs polymerize nicotinicamide adenine dinucleotides into branched polymers of ADP-ribose that are transferred to nuclear housekeeping proteins including DNA polymerase I and II,  $\text{Ca}^{2+}$ - $\text{Mg}^{2+}$ -endonuclease, histones, chromatin-binding proteins, and the PARPs themselves (for review, Chiarugi, *Trends Pharmacol. Sci.* 2002, 23: 122-129). These modifications are thought to facilitate the repair process of the DNA. Excessive activation of PARPs may ultimately drive cells into energy crisis due to depletion of nicotinicamide adenine dinucleotide pools and eventually elicit cell death. In fact, small-molecule inhibitors of PARPs hold therapeutic promise as anti-apoptotic drugs (Szabo et al., *Trends Pharmacol. Sci.* 1998, 19: 287-298; Pieper et al., *Trends Pharmacol. Sci.* 1999, 20: 171-181).

Kickhoefer and coworkers analysed the distribution of ADPRTL1/p193 messenger RNA in human tissues and found a prominent transcript in kidney, spleen, and liver but no transcript in brain (Kickhoefer et al., *J. Cell Biol.* 1999, 146: 917-928). In the present invention, using an unbiased and sensitive differential display approach, an ADPRTL1 transcript is detected in human brain samples. Importantly, the present invention discloses an up-regulation of ADPRTL1 transcripts in the inferior temporal lobe of brain samples taken from AD patients relative to frontal cortex samples. No such up-regulation is observed in samples from age-matched healthy controls. To date, no experiments have been described that show a relationship between a differential expression of the ADPRTL1 gene and the pathology of neurodegenerative diseases, particularly AD. Likewise, no experiments have been described that demonstrate a link between the dysregulation of vault gene expression and neurodegenerative disorders. Such a link offers new ways, inter alia, for the diagnosis and treatment of said disorders, in particular AD.

The singular forms "a", "an", and "the" as used herein and in the claims include plural reference unless the context dictates otherwise. For example, "a cell" means as well a plurality of cells, and so forth. The term "and/or" as used in the present specification and in the claims implies that the phrases before and after this term are to be considered either as alternatives or in combination. For instance, the wording "determination of a level and/or an activity" means that either only a level, or only an activity, or both a level and an activity are determined. The term "level" as used herein is meant to comprise a gage of, or a measure of the amount of, or a concentration of a transcription product, for instance an mRNA, or a translation product, for instance a protein or polypeptide. The term "activity" as used herein shall be understood as a measure for the ability of a transcription product or a translation product to produce a biological effect or a measure for a level of biologically active molecules. The term "activity" also refers to enzymatic activity. The terms "level" and/or "activity" as used herein further refer to gene expression levels or gene activity. Gene expression can be defined as the utilization of the information contained in a gene by transcription and translation leading to the production of a gene product. "Dysregulation" shall mean an upregulation or downregulation of gene expression. A gene product comprises either RNA or protein and is the result of expression of a gene. The amount of a gene product can be used to measure how active a gene is. The term "gene" as used in the present specification and in the claims comprises both coding regions (exons) as well as non-coding regions (e.g. non-coding regulatory elements such as promoters or enhancers, introns, leader and trailer sequences). The term "ORF" is an acronym for "open reading frame" and refers to a nucleic acid sequence that does not possess a stop codon in at least one reading frame and therefore can potentially be translated into a sequence of amino acids. "Regulatory elements" shall comprise inducible and non-inducible promoters, enhancers, operators, and other elements that drive and regulate gene expression. The term "fragment" as used herein is meant to comprise e.g. an alternatively spliced, or truncated, or otherwise cleaved transcription product or translation product. The term "derivative" as used herein refers to a mutant, or an RNA-edited, or a chemically modified, or otherwise altered transcription product, or to a mutant, or chemically modified, or otherwise altered translation product. For instance, a "derivative" may be generated by processes such as altered phosphorylation, or glycosylation, or acetylation, or lipidation, or by altered signal peptide cleavage or other types of maturation cleavage. These processes may occur

post-translationally. The term "modulator" as used in the present invention and in the claims refers to a molecule capable of changing or altering the level and/or the activity of a gene, or a transcription product of a gene, or a translation product of a gene. Preferably, a "modulator" is capable of changing or altering the biological activity of a transcription product or a translation product of a gene. Said modulation, for instance, may be an increase or a decrease in enzyme activity, a change in binding characteristics, or any other change or alteration in the biological, functional, or immunological properties of said translation product of a gene. The terms "agent", "reagent", or "compound" refer to any substance, chemical, composition or extract that have a positive or negative biological effect on a cell, tissue, body fluid, or within the context of any biological system, or any assay system examined. They can be agonists, antagonists, partial agonists or inverse agonists of a target. Such agents, reagents, or compounds may be nucleic acids, natural or synthetic peptides or protein complexes, or fusion proteins. They may also be antibodies, organic or inorganic molecules or compositions, small molecules, drugs and any combinations of any of said agents above. They may be used for testing, for diagnostic or for therapeutic purposes. The terms "oligonucleotide primer" or "primer" refer to short nucleic acid sequences which can anneal to a given target polynucleotide by hybridization of the complementary base pairs and can be extended by a polymerase. They may be chosen to be specific to a particular sequence or they may be randomly selected, e.g. they will prime all possible sequences in a mix. The length of primers used herein may vary from 10 nucleotides to 80 nucleotides. "Probes" are short nucleic acid sequences of the nucleic acid sequences described and disclosed herein or sequences complementary therewith. They may comprise full length sequences, or fragments, derivatives, isoforms, or variants of a given sequence. The identification of hybridization complexes between a "probe" and an assayed sample allows the detection of the presence of other similar sequences within that sample. As used herein, "homolog or homology" is a term used in the art to describe the relatedness of a nucleotide or peptide sequence to another nucleotide or peptide sequence, which is determined by the degree of identity and/or similarity between said sequences compared. The term "variant" as used herein refers to any polypeptide or protein, in reference to polypeptides and proteins disclosed in the present invention, in which one or more amino acids are added and/or substituted and/or deleted and/or inserted at the N-terminus, and/or the C-terminus, and/or within the native amino acid sequences of the native polypeptides or proteins of the present invention. Furthermore, the term "variant"



shall include any shorter or longer version of a polypeptide or protein. "Variants" shall also comprise a sequence that has at least about 80% sequence identity, more preferably at least about 90% sequence identity, and most preferably at least about 95% sequence identity with the amino acid sequences of the vault protein. "Variants" of a protein molecule include, for example, proteins with conservative amino acid substitutions in highly conservative regions. "Proteins and polypeptides" of the present invention include variants, fragments and chemical derivatives of the protein comprising the amino acid sequence of SEQ ID NO. 2. They can include proteins and polypeptides which can be isolated from nature or be produced by recombinant and/or synthetic means. Native proteins or polypeptides refer to naturally-occurring truncated or secreted forms, naturally occurring variant forms (e.g. splice-variants) and naturally occurring allelic variants. The term "isolated" as used herein is considered to refer to molecules that are removed from their natural environment, i.e. isolated from a cell or from a living organism in which they normally occur, and that are separated or essentially purified from the coexisting components with which they are found to be associated in nature. This notion further means that the sequences encoding such molecules can be linked by the hand of man to polynucleotides, to which they are not linked in their natural state, and that such molecules can be produced by recombinant and/or synthetic means. Even if for said purposes those sequences may be introduced into living or non-living organisms by methods known to those skilled in the art, and even if those sequences are still present in said organisms, they are still considered to be isolated. In the present invention, the terms "risk", "susceptibility", and "predisposition" are tantamount and are used with respect to the probability of developing a neurodegenerative disease, preferably Alzheimer's disease.

The term 'AD' shall mean Alzheimer's disease. "AD-type neuropathology" as used herein refers to neuropathological, neurophysiological, histopathological and clinical hallmarks as described in the instant invention and as commonly known from state-of-the-art literature (see: Iqbal, Swaab, Winblad and Wisniewski, *Alzheimer's Disease and Related Disorders (Etiology, Pathogenesis and Therapeutics)*, Wiley & Sons, New York, Weinheim, Toronto, 1999; Scinto and Daffner, *Early Diagnosis of Alzheimer's Disease*, Humana Press, Totowa, New Jersey, 2000; Mayeux and Christen, *Epidemiology of Alzheimer's Disease: From Gene to Prevention*, Springer Press, Berlin, Heidelberg, New York, 1999; Younkin, Tanzi and Christen, *Presenilins and Alzheimer's Disease*, Springer Press, Berlin, Heidelberg, New York, 1998).

Neurodegenerative diseases or disorders according to the present invention comprise Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Pick's disease, fronto-temporal dementia, progressive nuclear palsy, corticobasal degeneration, cerebro-vascular dementia, multiple system atrophy, argyrophilic grain dementia and other tauopathies, and mild-cognitive impairment. Further conditions involving neurodegenerative processes are, for instance, age-related macular degeneration, narcolepsy, motor neuron diseases, prion diseases, traumatic nerve injury and repair, and multiple sclerosis.

In one aspect, the invention features a method of diagnosing or prognosticating a neurodegenerative disease in a subject, or determining whether a subject is at increased risk of developing said disease. The method comprises: determining a level, or an activity, or both said level and said activity of (i) a transcription product of a gene coding for a vault protein, and/or of (ii) a translation product of a gene coding for a vault protein, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from said subject and comparing said level, and/or said activity to a reference value representing a known disease or health status, thereby diagnosing or prognosticating said neurodegenerative disease in said subject, or determining whether said subject is at increased risk of developing said neurodegenerative disease.

The invention also relates to the construction and the use of primers and probes which are unique to the nucleic acid sequences, or fragments, or variants thereof, as disclosed in the present invention. The oligonucleotide primers and/or probes can be labeled specifically with fluorescent, bioluminescent, magnetic, or radioactive substances. The invention further relates to the detection and the production of said nucleic acid sequences, or fragments and/or variants thereof, using said specific oligonucleotide primers in appropriate combinations. PCR-analysis, a method well known to those skilled in the art, can be performed with said primer combinations to amplify said gene specific nucleic acid sequences from a sample containing nucleic acids. Such sample may be derived either from healthy or diseased subjects. Whether an amplification results in a specific nucleic acid product or not, and whether a fragment of different length can be obtained or not, may be indicative for a neurodegenerative disease, in particular Alzheimer's disease. Thus, the invention provides nucleic acid sequences, oligonucleotide primers, and probes of at least 10 bases in length up to the entire coding and gene sequences, useful for the detection

of gene mutations and single nucleotide polymorphisms in a given sample comprising nucleic acid sequences to be examined, which may be associated with neurodegenerative diseases, in particular Alzheimer's disease. This feature has utility for developing rapid DNA-based diagnostic tests, preferably also in the format of a kit.

In a further aspect, the invention features a method of monitoring the progression of a neurodegenerative disease in a subject. A level, or an activity, or both said level and said activity, of (i) a transcription product of a gene coding for a vault protein, and/or of (ii) a translation product of a gene coding for a vault protein, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from said subject is determined. Said level and/or said activity is compared to a reference value representing a known disease or health status. Thereby the progression of said neurodegenerative disease in said subject is monitored.

In still a further aspect, the invention features a method of evaluating a treatment for a neurodegenerative disease, comprising determining a level, or an activity, or both said level and said activity of (i) a transcription product of a gene coding for a vault protein, and/or of (ii) a translation product of a gene coding for a vault protein, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample obtained from a subject being treated for said disease. Said level, or said activity, or both said level and said activity are compared to a reference value representing a known disease or health status, thereby evaluating the treatment for said neurodegenerative disease.

In a preferred embodiment of the herein claimed methods, kits, recombinant animals, molecules, assays, and uses of the instant invention, said gene coding for the vault protein is the gene coding for the minor vault protein particularly minor vault protein ADPRTL1, also termed p193. And it is preferred that said vault protein is a minor vault protein, particularly minor vault protein ADPRTL1, also called p193, SEQ ID NO.2.

In a further preferred embodiment of the herein claimed methods, kits, recombinant animals, molecules, assays, and uses of the instant invention, said neurodegenerative disease or disorder is Alzheimer's disease, and said subjects suffer from Alzheimer's disease.

The present invention discloses the differential expression and regulation of the minor vault protein ADPRTL1 gene in specific brain regions of AD patients. Consequently, the minor vault protein ADPRTL1 gene and its corresponding translation products may have a causative role in the regional selective neuronal degeneration typically observed in AD. Alternatively, the minor vault protein ADPRTL1 may confer a neuroprotective function to the remaining surviving nerve cells. Based on these disclosures, the present invention has utility for the diagnostic evaluation and prognosis as well as for the identification of a predisposition to a neurodegenerative disease, in particular AD. Furthermore, the present invention provides methods for the diagnostic monitoring of patients undergoing treatment for such a disease.

It is particularly preferred that said sample to be analyzed and determined is selected from the group comprising brain tissue or other tissues or body cells. The sample can also comprise cerebrospinal fluid or other body fluids including saliva, urine, serum plasma, or mucus. Preferably, the methods of diagnosis, prognosis, monitoring the progression or evaluating a treatment for a neurodegenerative disease, according to the instant invention, can be practiced *ex corpore*, and such methods preferably relate to samples, for instance, body fluids or cells, removed, collected, or isolated from a subject or patient.

In further preferred embodiments, said reference value is that of a level, or an activity, or both said level and said activity of (i) a transcription product of a gene coding for a vault protein, and/or of (ii) a translation product of a gene coding for a vault protein, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from a subject not suffering from said neurodegenerative disease.

In preferred embodiments, an alteration in the level and/or activity of a transcription product of the gene coding for ADPRTL1 and/or a translation product of the gene coding for ADPRTL1 in a sample cell, or tissue, or body fluid from said subject relative to a reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of becoming diseased with a neurodegenerative disease, particularly AD.

In preferred embodiments, measurement of the level of transcription products of a gene coding for a vault protein is performed in a sample from a subject using a quantitative PCR-analysis with primer combinations to amplify said gene specific sequences from cDNA obtained by reverse transcription of RNA extracted from a sample of a subject. A Northern blot with probes specific for said gene can also be applied. It might further be preferred to measure transcription products by means of chip-based micro-array technologies. These techniques are known to those of ordinary skill in the art (see Sambrook and Russell, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001; Schena M., *Microarray Biochip Technology*, Eaton Publishing, Natick, MA, 2000). An example of an immunoassay is the detection and measurement of enzyme activity as disclosed and described in the patent application WO 02/14543.

Furthermore, a level and/or an activity of a translation product of a gene coding for a vault protein and/or a fragment, or derivative, or variant of said translation product, and/or the level of activity of said translation product, and/or a fragment, or derivative, or variant thereof, can be detected using an immunoassay, an activity assay, and/or a binding assay. These assays can measure the amount of binding between said protein molecule and an anti-protein antibody by the use of enzymatic, chromodynamic, radioactive, magnetic, or luminescent labels which are attached to either the anti-protein antibody or a secondary antibody which binds the anti-protein antibody. In addition, other high affinity ligands may be used. Immunoassays which can be used include e.g. ELISAs, Western blots and other techniques known to those of ordinary skill in the art (see Harlow and Lane, *Using Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1999 and Edwards R, *Immunodiagnosics: A Practical Approach*, Oxford University Press, Oxford; England, 1999). All these detection techniques may also be employed in the format of microarrays, protein-arrays, antibody microarrays, tissue microarrays, electronic biochip or protein-chip based technologies (see Schena M., *Microarray Biochip Technology*, Eaton Publishing, Natick, MA, 2000).

In a preferred embodiment, the level, or the activity, or both said level and said activity of (i) a transcription product of a gene coding for a vault protein, and/or of (ii) a translation product of a gene coding for a vault protein, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a series of samples taken from said subject over a period of time is compared, in

order to monitor the progression of said disease. In further preferred embodiments, said subject receives a treatment prior to one or more of said sample gatherings. In yet another preferred embodiment, said level and/or activity is determined before and after said treatment of said subject.

In another aspect, the invention features a kit for diagnosing or prognosticating neurodegenerative diseases, in particular AD, in a subject, or determining the propensity or predisposition of a subject to develop a neurodegenerative disease, in particular AD, said kit comprising:

(a) at least one reagent which is selected from the group consisting of (i) reagents that selectively detect a transcription product of a gene coding for a vault protein (ii) reagents that selectively detect a translation product of a gene coding for a vault protein; and

(b) instruction for diagnosing, or prognosticating a neurodegenerative disease, in particular AD, or determining the propensity or predisposition of a subject to develop such a disease by

- detecting a level, or an activity, or both said level and said activity, of said transcription product and/or said translation product of a gene coding for a vault protein, in a sample from said subject; and
- diagnosing or prognosticating a neurodegenerative disease, in particular AD, or determining the propensity or predisposition of said subject to develop such a disease,

wherein a varied level, or activity, or both said level and said activity, of said transcription product and/or said translation product compared to a reference value representing a known health status; or a level, or activity, or both said level and said activity, of said transcription product and/or said translation product similar or equal to a reference value representing a known disease status, indicates a diagnosis or prognosis of a neurodegenerative disease, in particular AD, or an increased propensity or predisposition of developing such a disease. The kit, according to the present invention, may be particularly useful for the identification of individuals that are at risk of developing a neurodegenerative disease, in particular AD. Consequently, the kit, according to the invention, may serve as a means for targeting identified individuals for early preventive measures or therapeutic intervention prior to disease onset, before irreversible damage in the course of the disease has been inflicted. Furthermore, in preferred embodiments, the kit featured in the invention is useful for monitoring a progression of a neurodegenerative

disease, in particular AD in a subject, as well as monitoring success or failure of therapeutic treatment for such a disease of said subject.

In another aspect, the invention features a method of treating or preventing a neurodegenerative disease, in particular AD, in a subject comprising the administration to said subject in a therapeutically or prophylactically effective amount of an agent or agents which directly or indirectly affect a level, or an activity, or both said level and said activity, of (i) a gene coding for a vault protein, and/or (ii) a transcription product of a gene coding for a vault protein, and/or (iii) a translation product of a gene coding for a vault protein, and/or (iv) a fragment, or derivative, or variant of (i) to (iii). Said agent may comprise a small molecule, or it may also comprise a peptide, an oligopeptide, or a polypeptide. Said peptide, oligopeptide, or polypeptide may comprise an amino acid sequence of a translation product of a gene coding for a vault protein, or a fragment, or derivative, or a variant thereof. An agent for treating or preventing a neurodegenerative disease, in particular AD, according to the instant invention, may also consist of a nucleotide, an oligonucleotide, or a polynucleotide. Said oligonucleotide or polynucleotide may comprise a nucleotide sequence of the gene coding for a vault protein, either in sense orientation or in antisense orientation.

In preferred embodiments, the method comprises the application of per se known methods of gene therapy and/or antisense nucleic acid technology to administer said agent or agents. In general, gene therapy includes several approaches: molecular replacement of a mutated gene, addition of a new gene resulting in the synthesis of a therapeutic protein, and modulation of endogenous cellular gene expression by recombinant expression methods or by drugs. Gene-transfer techniques are described in detail (see e.g. Behr, *Acc Chem Res* 1993, 26: 274-278 and Mulligan, *Science* 1993, 260: 926-931) and include direct gene-transfer techniques such as mechanical microinjection of DNA into a cell as well as indirect techniques employing biological vectors (like recombinant viruses, especially retroviruses) or model liposomes, or techniques based on transfection with DNA coprecipitation with polycations, cell membrane perturbation by chemical (solvents, detergents, polymers, enzymes) or physical means (mechanic, osmotic, thermic, electric shocks). The postnatal gene transfer into the central nervous system has been described in detail (see e.g. Wolff, *Curr Opin Neurobiol* 1993, 3: 743-748).

In particular, the invention features a method of treating or preventing a neurodegenerative disease by means of antisense nucleic acid therapy, i.e. the down-regulation of an inappropriately expressed or defective gene by the introduction of antisense nucleic acids or derivatives thereof into certain critical cells (see e.g. Gillespie, *DN&P* 1992, 5: 389-395; Agrawal and Akhtar, *Trends Biotechnol* 1995, 13: 197-199; Crooke, *Biotechnology* 1992, 10: 882-6). Apart from hybridization strategies, the application of ribozymes, i.e. RNA molecules that act as enzymes, destroying RNA that carries the message of disease has also been described (see e.g. Barinaga, *Science* 1993, 262: 1512-1514; the contents of which are incorporated herein by reference). In preferred embodiments, the subject to be treated is a human, and therapeutic antisense nucleic acids or derivatives thereof are directed against transcripts of a gene coding for a vault protein, particularly the minor vault protein ADPRTL1. It is preferred that cells of the central nervous system, preferably the brain, of a subject are treated in such a way. Cell penetration can be performed by known strategies such as coupling of antisense nucleic acids and derivatives thereof to carrier particles, or the above described techniques. Strategies for administering targeted therapeutic oligo-deoxynucleotides are known to those of skill in the art (see e.g. Wickstrom, *Trends Biotechnol* 1992, 10: 281-287). In some cases, delivery can be performed by mere topical application. Further approaches are directed to intracellular expression of antisense RNA. In this strategy, cells are transformed *ex vivo* with a recombinant gene that directs the synthesis of an RNA that is complementary to a region of target nucleic acid. Therapeutical use of intracellularly expressed antisense RNA is procedurally similar to gene therapy. A recently developed method of regulating the intracellular expression of genes by the use of double-stranded RNA, known variously as RNA interference (RNAi), can be another effective approach for nucleic acid therapy (Hannon, *Nature* 2002, 418: 244-251).

In further preferred embodiments, the method comprises grafting donor cells into the central nervous system, preferably the brain, of said subject, or donor cells preferably treated so as to minimize or reduce graft rejection, wherein said donor cells are genetically modified by insertion of at least one transgene encoding said agent or agents. Said transgene might be carried by a viral vector, in particular a retroviral vector. The transgene can be inserted into the donor cells by a nonviral physical transfection of DNA encoding a transgene, in particular by microinjection. Insertion of the transgene can also be performed by electroporation, chemically



mediated transfection, in particular calcium phosphate transfection or liposomal mediated transfection (see Mc Celland and Pardee, *Expression Genetics: Accelerated and High-Throughput Methods*, Eaton Publishing, Natick, MA, 1999).

In preferred embodiments, said agent for treating and preventing a neurodegenerative disease, in particular AD, is a therapeutic protein which can be administered to said subject, preferably a human, by a process comprising introducing subject cells into said subject, said subject cells having been treated *in vitro* to insert a DNA segment encoding said therapeutic protein, said subject cells expressing *in vivo* in said subject a therapeutically effective amount of said therapeutic protein. Said DNA segment can be inserted into said cells *in vitro* by a viral vector, in particular a retroviral vector.

Methods of treatment, according to the present invention, comprise the application of therapeutic cloning, transplantation, and stem cell therapy using embryonic stem cells or embryonic germ cells and neuronal adult stem cells, combined with any of the previously described cell- and gene therapeutic methods. Stem cells may be totipotent or pluripotent. They may also be organ-specific. Strategies for repairing diseased and/or damaged brain cells or tissue comprise (i) taking donor cells from an adult tissue. Nuclei of those cells are transplanted into unfertilized egg cells from which the genetic material has been removed. Embryonic stem cells are isolated from the blastocyst stage of the cells which underwent somatic cell nuclear transfer. Use of differentiation factors then leads to a directed development of the stem cells to specialized cell types, preferably neuronal cells (Lanza et al., *Nature Medicine* 1999, 9: 975-977), or (ii) purifying adult stem cells, isolated from the central nervous system, or from bone marrow (mesenchymal stem cells), for *in vitro* expansion and subsequent grafting and transplantation, or (iii) directly inducing endogenous neural stem cells to proliferate, migrate, and differentiate into functional neurons (Peterson DA, *Curr. Opin. Pharmacol.* 2002, 2: 34-42). Adult neural stem cells are of great potential for repairing damaged or diseased brain tissues, as the germinal centers of the adult brain are free of neuronal damage or dysfunction (Colman A, *Drug Discovery World* 2001, 7: 66-71).

In preferred embodiments, the subject for treatment or prevention, according to the present invention, can be a human, an experimental animal, e.g. a mouse or a rat, a domestic animal, or a non-human primate. The experimental animal can be an

animal model for a neurodegenerative disorder, e.g. a transgenic mouse and/or a knock-out mouse with an AD-type neuropathology.

In a further aspect, the invention features a modulator of an activity, or a level, or both said activity and said level of at least one substance which is selected from the group consisting of (i) a gene coding for a vault protein, and/or (ii) a transcription product of a gene coding for a vault protein and/or (iii) a translation product of a gene coding for a vault protein, and/or (iv) a fragment, or derivative, or variant of (i) to (iii).

In an additional aspect, the invention features a pharmaceutical composition comprising said modulator and preferably a pharmaceutical carrier. Said carrier refers to a diluent, adjuvant, excipient, or vehicle with which the modulator is administered.

In a further aspect, the invention features a modulator of an activity, or a level, or both said activity and said level of at least one substance which is selected from the group consisting of (i) a gene coding for a vault protein, and/or (ii) a transcription product of a gene coding for a vault protein, and/or (iii) a translation product of a gene coding for a vault protein, and/or (iv) a fragment, or derivative, or variant of (i) to (iii) for use in a pharmaceutical composition.

In another aspect, the invention provides for the use of a modulator of an activity, or a level, or both said activity and said level of at least one substance which is selected from the group consisting of (i) a gene coding for a vault protein, and/or (ii) a transcription product of a gene coding for a vault protein and/or (iii) a translation product of a gene coding for a vault protein, and/or (iv) a fragment, or derivative, or variant of (i) to (iii) for a preparation of a medicament for treating or preventing a neurodegenerative disease, in particular AD.

In one aspect, the present invention also provides a kit comprising one or more containers filled with a therapeutically or prophylactically effective amount of said pharmaceutical composition.

In a further aspect, the invention features a recombinant, non-human animal comprising a non-native gene sequence coding for a vault protein, or a fragment, or

a derivative thereof. The generation of said recombinant, non-human animal comprises (i) providing a gene targeting construct containing said gene sequence and a selectable marker sequence, and (ii) introducing said targeting construct into a stem cell of a non-human animal, and (iii) introducing said non-human animal stem cell into a non-human embryo, and (iv) transplanting said embryo into a pseudopregnant non-human animal, and (v) allowing said embryo to develop to term, and (vi) identifying a genetically altered non-human animal whose genome comprises a modification of said gene sequence in both alleles, and (vii) breeding the genetically altered non-human animal of step (vi) to obtain a genetically altered non-human animal whose genome comprises a modification of said endogenous gene, wherein said gene is mis-expressed, or under-expressed, or over-expressed, and wherein said disruption or alteration results in said non-human animal exhibiting a predisposition to developing symptoms of neuropathology similar to a neurodegenerative disease, in particular AD. Strategies and techniques for the generation and construction of such an animal are known to those of ordinary skill in the art (see e.g. Capecchi, *Science* 1989, 244: 1288-1292 and Hogan et al., 1994, *Manipulating the Mouse Embryo: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York and Jackson and Abbott, *Mouse Genetics and Transgenics: A Practical Approach*, Oxford University Press, Oxford, England, 1999). It is preferred to make use of such a recombinant non-human animal as an animal model for investigating neurodegenerative diseases, in particular AD. Such an animal may be useful for screening, testing and validating compounds, agents and modulators in the development of diagnostics and therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease. In preferred embodiments, said recombinant, non-human animal comprises a non-native gene sequence coding for a vault protein, in particular the non-native minor vault protein ADPRTL1 gene sequence, or a fragment thereof.

In another aspect, the invention features an assay for screening for a modulator of neurodegenerative diseases, in particular AD, or related diseases and disorders of one or more substances selected from the group consisting of (i) a gene coding for a vault protein, and/or (ii) a transcription product of a gene coding for a vault protein, and/or (iii) a translation product of a gene coding for a vault protein, and/or (iv) a fragment, or derivative, or variant of (i) to (iii). This screening method comprises (a) contacting a cell with a test compound, and (b) measuring the activity, or the level, or both the activity and the level of one or more substances recited in (i) to (iv), and

(c) measuring the activity, or the level, or both the activity and the level of said substances in a control cell not contacted with said test compound, and (d) comparing the levels of the substance in the cells of step (b) and (c), wherein an alteration in the activity and/or level of said substances in the contacted cells indicates that the test compound is a modulator of said diseases and disorders.

In one further aspect, the invention features a screening assay for a modulator of neurodegenerative diseases, in particular AD, or related diseases and disorders of one or more substances selected from the group consisting of (i) a gene coding for a vault protein, and/or (ii) a transcription product of a gene coding for a vault protein, and/or (iii) a translation product of a gene coding for a vault protein, and/or (iv) a fragment, or derivative, or variant of (i) to (iii), comprising (a) administering a test compound to a test animal which is predisposed to developing or has already developed symptoms of a neurodegenerative disease or related diseases or disorders, and (b) measuring the activity and/or level of one or more substances recited in (i) to (iv), and (c) measuring the activity and/or level of said substances in a matched control animal which is equally predisposed to developing or has already developed symptoms of said diseases and to which animal no such test compound has been administered, and (d) comparing the activity and/or level of the substance in the animals of step (b) and (c), wherein an alteration in the activity and/or level of substances in the test animal indicates that the test compound is a modulator of said diseases and disorders.

In a preferred embodiment, said test animal and/or said control animal is a recombinant, non-human animal which expresses a gene coding for a vault protein, or a fragment, or a derivative, or a variant thereof, under the control of a transcriptional regulatory element which is not the native vault protein gene transcriptional control regulatory element.

In another embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a modulator of neurodegenerative diseases by a method of the aforementioned screening assays and (ii) admixing the modulator with a pharmaceutical carrier. However, said modulator may also be identifiable by other types of screening assays.

In another aspect, the present invention provides for an assay for testing a compound, preferably for screening a plurality of compounds, for inhibition of binding between a ligand and a vault protein, or a fragment, or derivative, or variant thereof. Said screening assay comprises the steps of (i) adding a liquid suspension of said vault protein, or a fragment, or derivative, or variant thereof, to a plurality of containers, and (ii) adding a compound or a plurality of compounds to be screened for said inhibition to said plurality of containers, and (iii) adding fluorescently labelled ligand to said containers, and (iv) incubating said vault protein, or said fragment, or derivative, or variant thereof, and said compound or plurality of compounds, and said fluorescently labelled ligand, and (v) measuring the amounts of fluorescence associated with said vault protein, or with said fragment, or derivative, or variant thereof, and (vi) determining the degree of inhibition by one or more of said compounds of binding of said ligand to said vault protein, or said fragment, or derivative, or variant thereof. Instead of utilizing a fluorescently labelled ligand, it might in some aspects be preferred to use any other detectable label known to the person skilled in the art, e.g. radioactive labels, and detect it accordingly. Said method may be useful for the identification of novel compounds as well as for evaluating compounds which have been improved or otherwise optimized in their ability to inhibit the binding of a ligand to a gene product of a gene coding for a vault protein, or a fragment, or derivative, or variant thereof. One example of a fluorescent binding assay, in this case based on the use of carrier particles, is disclosed and described in patent application WO 00/52451. A further example is the competitive assay method as described in patent WO 02/01226. Preferred signal detection methods for screening assays of the instant invention are described in the following patent applications: WO 96/13744, WO 98/16814, WO 98/23942, WO 99/17086, WO 99/34195, WO 00/66985, WO 01/59436, WO 01/59416.

In one further embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a compound as an inhibitor of binding between a ligand and a gene product of a gene coding for a vault protein by the aforementioned inhibitory binding assay and (ii) admixing the compound with a pharmaceutical carrier. However, said compound may also be identifiable by other types of screening assays.

In another aspect, the invention features an assay for testing a compound, preferably for screening a plurality of compounds to determine the degree of binding

of said compounds to a vault protein, or to a fragment, or derivative, or variant thereof. Said screening assay comprises (i) adding a liquid suspension of said vault protein, or a fragment, or derivative, or variant thereof, to a plurality of containers, and (ii) adding a fluorescently labelled compound or a plurality of fluorescently labelled compounds to be screened for said binding to said plurality of containers, and (iii) incubating said vault protein, or said fragment, or derivative, or variant thereof, and said fluorescently labelled compound or fluorescently labelled compounds, and (iv) measuring the amounts of fluorescence associated with said vault protein, or with said fragment, or derivative, or variant thereof, and (v) determining the degree of binding by one or more of said compounds to said vault protein, or said fragment, or derivative, or variant thereof. In this type of assay it might be preferred to use a fluorescent label. However, any other type of detectable label might also be employed. Said method may be useful for the identification of novel compounds as well as for evaluating compounds which have been improved or otherwise optimized in their ability to bind to a vault protein, or a fragment, or derivative, or variant thereof.

In one further embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a compound as a binder to a gene product of a gene coding for a vault protein by the aforementioned binding assays and (ii) admixing the compound with a pharmaceutical carrier. However, said compound may also be identifiable by other types of screening assays.

In another embodiment, the present invention provides for a medicament obtainable by any of the methods according to the herein claimed screening assays. In one further embodiment, the instant invention provides for a medicament obtained by any of the methods according to the herein claimed screening assays.

The present invention features a protein molecule shown in SEQ ID NO. 2, said protein molecule being a translation product of the gene coding for a vault protein, in particular the minor vault protein ADPRTL1, or a fragment, or derivative, or variant thereof, for use as a diagnostic target for detecting a neurodegenerative disease, preferably Alzheimer's disease.

The present invention further features a protein molecule shown in SEQ ID NO. 2, said protein molecule being a translation product of the gene coding for a vault

protein, in particular the minor vault protein ADPRTL1, or a fragment, or derivative, or variant thereof, for use as a screening target for reagents or compounds preventing, or treating, or ameliorating a neurodegenerative disease, preferably Alzheimer's disease.

In all types of assays disclosed herein it is preferred to study a vault protein. It is particularly preferred to conduct screening assays with the minor vault protein ADPRTL1.

The present invention features an antibody which is specifically immunoreactive with an immunogen, wherein said immunogen is a translation product of a gene coding for a vault protein, in particular the minor vault protein ADPRTL1, SEQ ID NO. 2, or a fragment, or derivative, or variant thereof. The immunogen may comprise immunogenic or antigenic epitopes or portions of a translation product of said gene, wherein said immunogenic or antigenic portion of a translation product is a polypeptide, and wherein said polypeptide elicits an antibody response in an animal, and wherein said polypeptide is immunospecifically bound by said antibody. Methods for generating antibodies are well known in the art (see Harlow et al., *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1988). The term "antibody", as employed in the present invention, encompasses all forms of antibodies known in the art, such as polyclonal, monoclonal, chimeric, recombinatorial, anti-idiotypic, humanized, or single chain antibodies, as well as fragments thereof (see Dubel and Breitling, *Recombinant Antibodies*, Wiley-Liss, New York, NY, 1999). Antibodies of the present invention are useful, for instance, in a variety of diagnostic and therapeutic methods, based on state-in-the-art techniques (see Harlow and Lane, *Using Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1999 and Edwards R., *Immunodiagnosics: A Practical Approach*, Oxford University Press, Oxford, England, 1999) such as enzyme-immuno assays (e.g. enzyme-linked immunosorbent assay, ELISA), radioimmuno assays, chemoluminescence-immuno assays, Western-blot, immunoprecipitation and antibody microarrays. These methods involve the detection of translation products of a gene coding for a vault protein, in particular the minor vault protein ADPRTL1.

In a preferred embodiment of the present invention, said antibodies can be used for detecting the pathological state of a cell in a sample from a subject, comprising

immunocytochemical staining of said cell with said antibody, wherein an altered degree of staining, or an altered staining pattern in said cell compared to a cell representing a known health status indicates a pathological state of said cell. Preferably, the pathological state relates to a neurodegenerative disease, in particular to AD. Immunocytochemical staining of a cell can be carried out by a number of different experimental methods well known in the art. It might be preferred, however, to apply an automated method for the detection of antibody binding, wherein the determination of the degree of staining of a cell, or the determination of the cellular or subcellular staining pattern of a cell, or the topological distribution of an antigen on the cell surface or among organelles and other subcellular structures within the cell, are carried out according to the method described in US patent 6150173.

Other features and advantages of the invention will be apparent from the following description of figures and examples which are illustrative only and not intended to limit the remainder of the disclosure in any way.

Figure 1 depicts the brain regions with selective vulnerability to neuronal loss and degeneration in AD. Primarily, neurons within the inferior temporal lobe, the entorhinal cortex, the hippocampus, and the amygdala are subject to degenerative processes in AD (Terry et al., *Annals of Neurology* 1981, 10:184-192). These brain regions are mostly involved in the processing of learning and memory functions. In contrast, neurons within the frontal cortex, the occipital cortex, and the cerebellum remain largely intact and preserved from neurodegenerative processes in AD. Brain tissues from the frontal cortex (F), the temporal cortex (T) and the hippocampus (H) of AD patients and healthy, age-matched control individuals were used for the herein disclosed examples. For illustrative purposes, the image of a normal healthy brain was taken from a publication by Strange (*Brain Biochemistry and Brain Disorders*, Oxford University Press, Oxford, 1992, p.4).

Figure 2 discloses the initial identification of the differential expression of the human gene coding for minor vault protein ADPRTL1 in a fluorescence differential display screen. The figure shows a clipping of a large preparative fluorescent differential display gel. PCR products from the frontal cortex (F) and the temporal cortex (T) of two healthy control subjects and six AD patients were loaded in duplicate onto a denaturing polyacrylamide gel (from left to right). PCR products were obtained by



amplification of the individual cDNAs with the corresponding one-base-anchor oligonucleotide and the specific Cy3 labelled random primers. The arrow indicates the migration position where significant differences in intensity of the signals for human minor vault protein ADPRTL1 transcript derived from frontal cortex as compared to the signals derived from the temporal cortex of AD patients exist. The differential expression reflects an up-regulation of human minor vault protein ADPRTL1 gene transcription in the temporal cortex compared to the frontal cortex of AD patients. Comparing the signals derived from temporal cortex and frontal cortex of healthy non-AD control subjects with each other, no difference in signal intensity, i.e. no altered expression level can be detected.

Figure 3 and 4 illustrate the verification of the differential expression of the minor vault protein ADPRTL1 gene in AD brain tissues by quantitative RT-PCR analysis. Quantification of RT-PCR products from RNA samples collected from the frontal cortex (F) and the temporal cortex (T) of AD patients (Figure 3a) and samples from the frontal cortex (F) and the hippocampus (H) of AD patients (Figure 4a) was performed by the LightCycler rapid thermal cycling technique. Likewise, samples of healthy, age-matched control individuals were compared (Figure 3b for frontal cortex and temporal cortex, Figure 4b for frontal cortex and hippocampus). The data were normalized to the combined average values of a set of standard genes which showed no significant differences in their gene expression levels. Said set of standard genes consisted of genes for the ribosomal protein S9, cyclophilin B, the transferrin receptor, GAPDH, and beta-actin. The figures depict the kinetics of amplification by plotting the cycle number against the amount of amplified material as measured by its fluorescence. Note that the amplification kinetics of the minor vault protein ADPRTL1 cDNA from both, the frontal and temporal cortices of a normal control individual, and from the frontal cortex and hippocampus of a normal control individual, respectively, during the exponential phase of the reaction are juxtaposed (Figures 3b and 4b, arrowheads), whereas in AD (Figures 3a and 4a, arrowheads) there is a significant separation of the corresponding curves, indicating an up-regulation of the minor vault protein ADPRTL1 mRNA expression in temporal cortex relative to frontal cortex in the respective analyzed brain regions.

Figure 5 depicts SEQ ID NO. 1, the nucleotide sequence of the 35 bp minor vault protein ADPRTL1 cDNA fragment, identified and obtained by fluorescence differential display and subsequent cloning.

Figure 6 charts the schematic alignment of SEQ ID NO. 1 to the nucleotide sequence of the minor vault protein ADPRTL1 cDNA (GenBank accession number AF057160). The open rectangle represents the minor vault protein ADPRTL1 open reading frame, thin bars represent the 5' and 3' untranslated regions (UTRs).

Figure 7 outlines the sequence alignment of SEQ ID NO. 1 to the nucleotide sequence of the minor vault protein ADPRTL1 cDNA (GenBank accession number AF057160).

Figure 8 discloses SEQ ID NO. 2, the amino acid sequence of the minor vault protein ADPRTL1 (GenBank accession number Q9UKK3). The full-length human minor vault protein ADPRTL1 comprises 1724 amino acids.

Figure 9 depicts human cerebral cortex labeled with anti-ADPRTL1 mouse monoclonal antibodies (green signals). Immunoreactivity of ADPRTL1 was detected in the pre-central cortex (CT) as well as in the white matter (WM) (Figure 9a, low magnification). The cortex showed punctate immunoreactive signals of ADPRTL1 which were detected in both neuronal and glial cytoplasm (Figure 9b, high magnification). The white matter exhibited immunopositive signals in the cytoplasm of many glial cells. Blue signals indicate nuclei stained with DAPI.

Table 1 lists the gene expression levels in the temporal cortex relative to the frontal cortex for the minor vault protein ADPRTL1 gene in seven AD patients, herein identified by internal reference numbers P010, P011, P012, P014, P016, P017, P019 (0.91 to 1.69 fold) and five healthy, age-matched control individuals, herein identified by internal reference numbers C005, C008, C011, C012, C014 (0.77 to 1.23 fold). The scatter diagram points up the single values and the mean average value (indicated by a solid line) of the temporal to frontal cortex regulation ratios in control samples (dots) and in AD patient samples (triangles), respectively.

Table 2 lists the minor vault protein ADPRTL1 gene expression levels in the hippocampus relative to the frontal cortex in six Alzheimer's disease patients, herein identified by internal reference numbers P010, P011, P012, P014, P016, P019 (1.24 to 2.11 fold) and three healthy, age-matched control individuals, herein identified by internal reference numbers C004, C005, C008 (1.28 to 1.86 fold). The scatter

diagram points up the single values and the mean average value (indicated by a solid line) of the hippocampus to frontal cortex regulation ratios in control samples (dots) and in AD patient samples (triangles), respectively.

#### EXAMPLE I:

##### (i) Brain tissue dissection from patients with AD:

Brain tissues from AD patients and age-matched control subjects were collected within 6 hours post-mortem and immediately frozen on dry ice. Sample sections from each tissue were fixed in paraformaldehyde for histopathological confirmation of the diagnosis. Brain areas for differential expression analysis were identified (see Figure 1) and stored at -80 °C until RNA extractions were performed.

##### (ii) Isolation of total mRNA:

Total RNA was extracted from post-mortem brain tissue by using the RNeasy kit (Qiagen) according to the manufacturer's protocol. The accurate RNA concentration and the RNA quality were determined with the DNA LabChip system using the Agilent 2100 Bioanalyzer (Agilent Technologies). For additional quality testing of the prepared RNA, i.e. exclusion of partial degradation and testing for DNA contamination, specifically designed intronic GAPDH oligonucleotides and genomic DNA as reference control were utilised to generate a melting curve with the LightCycler technology as described in the supplied protocol by the manufacturer (Roche).

##### (iii) cDNA synthesis and identification of differentially expressed genes by fluorescence differential display (FDD):

In order to identify changes in gene expression in different tissues we employed a modified and improved differential display (DD) screening method. The original DD screening method is known to those skilled in the art (Liang and Pardee, *Science* 1995, 267:1186-7). This technique compares two populations of RNA and provides clones of genes that are expressed in one population but not in the other. Several samples can be analyzed simultaneously and both up- and down-regulated genes can be identified in the same experiment. By adjusting and refining several steps in the DD method as well as modifying technical parameters, e.g. increasing redundancy, evaluating optimized reagents and conditions for reverse transcription

of total RNA, optimizing polymerase chain reactions (PCR) and separation of the products thereof, a technique was developed which allows for highly reproducible and sensitive results. The applied and improved DD technique was described in detail by von der Kammer et al. (*Nucleic Acids Research* 1999, 27: 2211-2218). A set of 64 specifically designed random primers were developed (standard set) to achieve a statistically comprehensive analysis of all possible RNA species. Further, the method was modified to generate a preparative DD slab-gel technique, based on the use of fluorescently labelled primers. In the present invention, RNA populations from carefully selected post-mortem brain tissues (frontal and temporal cortex) of AD patients and age-matched control subjects were compared.

As starting material for the DD analysis we used total RNA, extracted as described above (ii). Equal amounts of 0.05 µg RNA each were transcribed into cDNA in 20 µl reactions containing 0.5 mM each dNTP, 1 µl Sensiscript Reverse Transcriptase and 1x RT buffer (Qiagen), 10 U RNase inhibitor (Qiagen) and 1 µM of either one-base-anchor oligonucleotides HT<sub>11</sub>A, HT<sub>11</sub>G or HT<sub>11</sub>C (Liang et al., *Nucleic Acids Research* 1994, 22: 5763-5764; Zhao et al., *Biotechniques* 1995, 18: 842-850). Reverse transcription was performed for 60 min at 37 °C with a final denaturation step at 93 °C for 5 min. 2 µl of the obtained cDNA each was subjected to a polymerase chain reaction (PCR) employing the corresponding one-base-anchor oligonucleotide (1 µM) along with either one of the Cy3 labelled random DD primers (1 µM), 1x GeneAmp PCR buffer (Applied Biosystems), 1.5 mM MgCl<sub>2</sub> (Applied Biosystems), 2 µM dNTP-Mix (dATP, dGTP, dCTP, dTTP Amersham Pharmacia Biotech), 5 % DMSO (Sigma), 1 U AmpliTaq DNA Polymerase (Applied Biosystems) in a 20 µl final volume. PCR conditions were set as follows: one round at 94 °C for 30 sec for denaturing, cooling 1 °C/sec down to 40 °C, 40 °C for 4 min for low-stringency annealing of primer, heating 1 °C/sec up to 72 °C, 72 °C for 1 min for extension. This round was followed by 39 high-stringency cycles: 94 °C for 30 sec, cooling 1 °C/sec down to 60 °C, 60 °C for 2 min, heating 1 °C/sec up to 72 °C, 72 °C for 1 min. One final step at 72 °C for 5 min was added to the last cycle (PCR cycler: Multi Cycler PTC 200, MJ Research). 8 µl DNA loading buffer were added to the 20 µl PCR product preparation, denatured for 5 min and kept on ice until loading onto a gel. 3.5 µl each were separated on 0.4 mm thick, 6 %-polyacrylamide (Long Ranger)/ 7 M urea sequencing gels in a slab-gel system (Hitachi Genetic Systems) at 2000 V, 60W, 30 mA, for 1 h 40 min. Following completion of the electrophoresis, gels were scanned with a FMBIO II fluorescence-scanner (Hitachi Genetic Systems),

using the appropriate FMBIO II Analysis 8.0 software. A full-scale picture was printed, differentially expressed bands marked, excised from the gel, transferred into 1.5 ml containers, overlaid with 200  $\mu$ l sterile water and kept at  $-20^{\circ}\text{C}$  until extraction.

**Elution and reamplification of DD products:** The differential bands were extracted from the gel by boiling in 200  $\mu$ l  $\text{H}_2\text{O}$  for 10 min, cooling down on ice and precipitation from the supernatant fluids by using ethanol (Merck) and glycogen/sodium acetate (Merck) at  $-20^{\circ}\text{C}$  over night, and subsequent centrifugation at 13.000 rpm for 25 min at  $4^{\circ}\text{C}$ . Pellets were washed twice in ice-cold ethanol (80%), resuspended in 10 mM Tris pH 8.3 (Merck) and dialysed against 10 % glycerol (Merck) for 1 h at room temperature on a 0.025  $\mu\text{m}$  VSWP membrane (Millipore). The obtained preparations were used as templates for reamplification by 15 high-stringency cycles in 25- $\mu$ l PCR mixtures containing the corresponding primer pairs as used for the DD PCR (see above) under identical conditions, with the exception of the initial round at  $94^{\circ}\text{C}$  for 5 min, followed by 15 cycles of:  $94^{\circ}\text{C}$  for 45 sec,  $60^{\circ}\text{C}$  for 45 sec, ramp  $1^{\circ}\text{C}/\text{sec}$  to  $70^{\circ}\text{C}$  for 45 sec, and one final step at  $72^{\circ}\text{C}$  for 5 min.

**Cloning and sequencing of DD products:** Re-amplified cDNAs were analyzed with the DNA LabChip® system (Agilent 2100 Bioanalyzer, Agilent Technologies) and ligated into the pCR-Blunt II-TOPO vector and transformed into *E.coli* Top10F' cells (Zero Blunt TOPO PCR Cloning Kit, Invitrogen) according to the manufacturer's instructions. Cloned cDNA fragments were sequenced by commercially available sequencing facilities. The result of one such FDD experiment for the human minor vault protein ADPRTL1 gene is shown in Figure 2.

(iv) Confirmation of differential expression by quantitative RT-PCR:

Positive corroboration of differential expression of the human minor vault protein ADPRTL1 gene was performed using the LightCycler technology (Roche). This technique features rapid thermal cycling for the polymerase chain reaction as well as real-time measurement of fluorescent signals during amplification and therefore allows for highly accurate quantification of RT-PCR products by using a kinetic, rather than an endpoint readout. The ratios of human minor vault protein ADPRTL1 cDNA from the temporal cortex and frontal cortex, and from the hippocampus and frontal cortex, respectively, were determined (relative quantification).

First, a standard curve was generated to determine the efficiency of the PCR with specific primers for the human minor vault protein ADPRTL1 gene:

5'-GATGCTGTGCCTTGGACAGAA-3' and  
5'-TGGTGTAAGTTTCCAGAAGCCA-3'.

PCR amplification (95 °C and 1 sec, 56 °C and 5 sec, and 72 °C and 5 sec) was performed in a volume of 20 µl containing LightCycler-FastStart DNA Master SYBR Green I mix (contains FastStart Taq DNA polymerase, reaction buffer, dNTP mix with dUTP instead of dTTP, SYBR Green I dye, and 1 mM MgCl<sub>2</sub>; Roche), 0.5 µM primers, 2 µl of a cDNA dilution series (final concentration of 40, 20, 10, 5, 1 and 0.5 ng human total brain cDNA; Clontech) and, depending on the primers used, additional 3 mM MgCl<sub>2</sub>. Melting curve analysis revealed a single peak at approximately 82°C with no visible primer dimers. Quality and size of the PCR product were determined with the DNA LabChip system (Agilent 2100 Bioanalyzer, Agilent Technologies). A single peak at the expected size of 66 bp for the minor vault protein ADPRTL1 gene was observed in the electropherogram of the sample.

In an analogous manner, the PCR protocol was applied to determine the PCR efficiency of a set of reference genes which were selected as a reference standard for quantification. In the present invention, the mean value of five such reference genes was determined: (1) cyclophilin B, using the specific primers 5'-ACTGAAGCACTACGGGCCTG-3' and 5'-AGCCGTTGGTGTCTTTGCC-3' except for MgCl<sub>2</sub> (an additional 1 mM was added instead of 3 mM). Melting curve analysis revealed a single peak at approximately 87 °C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band of the expected size (62 bp). (2) Ribosomal protein S9 (RPS9), using the specific primers 5'-GGTCAAATTTACCCTGGCCA-3' and 5'-TCTCATCAAGCGTCAGCAGTTC-3' (exception: additional 1 mM MgCl<sub>2</sub> was added instead of 3 mM). Melting curve analysis revealed a single peak at approximately 85°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (62 bp). (3) beta-actin, using the specific primers 5'-TGGAACGGTGAAGGTGACA-3' and 5'-GGCAAGGGACTTCCTGTAA-3'. Melting curve analysis revealed a single peak at approximately 87°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (142 bp). (4) GAPDH, using the specific primers 5'-CGTCATGGGTGTGAACCATG-3' and 5'-GCTAAGCAGTTGGTGGTGCAG-3'. Melting curve analysis revealed a single peak at approximately 83°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (81 bp). (5) Transferrin receptor TRR, using the specific primers 5'-GTCGCTGGTCAGTTCGTGATT-3' and 5'-AGCAGTTGGCTGTTGTACCTCTC-3'.

Melting curve analysis revealed a single peak at approximately 83°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (80 bp).

For calculation of the values, first the logarithm of the cDNA concentration was plotted against the threshold cycle number  $C_t$  for minor vault protein ADPRTL1 and the five reference standard genes. The slopes and the intercepts of the standard curves (i.e. linear regressions) were calculated for all genes. In a second step, cDNAs from temporal cortex and frontal cortex, and from hippocampus and frontal cortex, respectively, were analyzed in parallel and normalized to cyclophilin B. The  $C_t$  values were measured and converted to ng total brain cDNA using the corresponding standard curves:

$$10^{((C_t \text{ value} - \text{intercept}) / \text{slope})} \quad [\text{ng total brain cDNA}]$$

The values for temporal and frontal cortex cDNAs, and the values for hippocampus and frontal cortex cDNAs of the minor vault protein ADPRTL1, respectively, were normalized to cyclophilin B, and the ratios were calculated using the following formulas:

$$\text{Ratio} = \frac{\text{ADPRTL1 temporal [ng]} / \text{cyclophilin B temporal [ng]}}{\text{ADPRTL1 frontal [ng]} / \text{cyclophilin B frontal [ng]}}$$

$$\text{Ratio} = \frac{\text{ADPRTL1 hippocampus [ng]} / \text{cyclophilin B hippocampus [ng]}}{\text{ADPRTL1 frontal [ng]} / \text{cyclophilin B frontal [ng]}}$$

In a third step, the set of reference standard genes was analyzed in parallel to determine the mean average value of the temporal to frontal ratios, and of the hippocampal to frontal ratios, respectively, of expression levels of the reference standard genes for each individual brain sample. As cyclophilin B was analyzed in step 2 and step 3, and the ratio from one gene to another gene remained constant in different runs, it was possible to normalize the values for the minor vault protein

ADPRTL1 to the mean average value of the set of reference standard genes instead of normalizing to one single gene alone. The calculation was performed by dividing the respective ratio shown above by the deviation of cyclophilin B from the mean value of all housekeeping genes. The results of such quantitative RT-PCR analysis for the minor vault protein ADPRTL1 gene are shown in Figure 3 and 4.

(v) Immunohistochemistry:

For immunofluorescence staining of ADPRTL1 in human brain, frozen sections were prepared from post-mortem pre-central gyrus of a donor person (Cryostat Leica CM3050S) and fixed in 4% paraformaldehyde at room temperature for 20 min. After washing in PBS, the sections were pre-incubated with 20 mM glycine in PBS for 10 min and treated with 6 N guanidine-HCL in 50 mM Tris-HCL, pH 7.5 for 10 min. Afterwards, the sections were incubated with blocking buffer (10% normal goat serum, 0.2% Triton X-100 in PBS) for 30min, and then incubated with anti-ADPRTL1 mouse monoclonal antibodies (1:20 diluted in blocking buffer; clone p193-6 from Chemicon International, Hofheim/Ts, Germany) overnight at 4°C. After rinsing three times in 0.1% Triton X-100/PBS, the sections were incubated with FITC-conjugated goat anti-mouse IgG (1:150 diluted in 1% BSA/PBS) for 2 hours at room temperature, and then again washed in PBS. Staining of the nuclei was performed by incubation of the sections with 5 $\mu$ M DAPI in PBS for 3min (blue signal). In order to block the autofluorescence of lipofuscin in human brain, the sections were treated with 1% Sudan Black B in 70% ethanol for 2-10 min at room temperature and sequentially dipped in 70% ethanol, distilled water, and PBS. The sections were coverslipped by 'Vectrashield mounting medium' (Vector Laboratories, Burlingame, CA) and observed under an inverted microscope (IX81, Olympus Optical). The digital images were captured with the appropriate software (AnalySiS, Olympus Optical).



## CLAIMS

1. A method of diagnosing or prognosticating a neurodegenerative disease in a subject, or determining whether a subject is at increased risk of developing said disease, comprising:

determining a level and/or an activity of

- (i) a transcription product of a gene coding for a vault protein, and/or
  - (ii) a translation product of a gene coding for a vault protein and/or
  - (iii) a fragment, or derivative, or variant of said transcription or translation product
- in a sample from said subject and comparing said level and/or said activity to a reference value representing a known disease or health status, thereby diagnosing or prognosticating said neurodegenerative disease in said subject, or determining whether said subject is at increased risk of developing said neurodegenerative disease.

2. A method of monitoring the progression of a neurodegenerative disease in a subject, comprising:

determining a level and/or an activity of

- (i) a transcription product of a gene coding for a vault protein, and/or
  - (ii) a translation product of a gene coding for a vault protein, and/or
  - (iii) a fragment, or derivative, or variant of said transcription or translation product
- in a sample from said subject and comparing said level and/or said activity to a reference value representing a known disease or health status, thereby monitoring the progression of said neurodegenerative disease in said subject.

3. A method of evaluating a treatment for a neurodegenerative disease, comprising:  
determining a level and/or an activity of

- (i) a transcription product of a gene coding for a vault protein, and/or
- (ii) a translation product of a gene coding for a vault protein, and/or
- (iii) a fragment, or derivative, or variant of said transcription or translation product,

in a sample from a subject being treated for said disease and comparing said level and/or said activity to a reference value representing a known disease or health status, thereby evaluating said treatment for said neurodegenerative disease.

4. The method according to any of claims 1 to 3 wherein said neurodegenerative disease is Alzheimer's disease.
5. The method according to any of claims 1 to 4 wherein said vault protein is a minor vault protein, in particular the minor vault protein ADPRTL1.
6. The method according to any of claims 1 to 5 wherein said sample comprises a cell, or a tissue, or a body fluid, in particular cerebrospinal fluid or blood.
7. The method according to any of claims 1 to 6 wherein said reference value is that of a level and/or an activity of
  - (i) a transcription product of a gene coding for a vault protein, and/or
  - (ii) a translation product of a gene coding for a vault protein, and/or
  - (iii) a fragment, or derivative, or variant of said transcription or translation product,in a sample from a subject not suffering from said neurodegenerative disease.
8. The method according to any of claims 1 to 7 wherein an alteration in the level and/or activity of a transcription product of the gene coding for the minor vault protein ADPRTL1 and/or a translation product of a gene coding for the minor vault protein ADPRTL1, and/or a fragment, or derivative, or variant thereof, in a sample cell, or tissue, or body fluid, in particular cerebrospinal fluid, from said subject relative to a reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.
9. A kit for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or determining the propensity or predisposition of a subject to develop such a disease, said kit comprising:
  - (a) at least one reagent which is selected from the group consisting of (i) reagents that selectively detect a transcription product of a gene coding for a vault protein and (ii) reagents that selectively detect a translation product of a gene coding for a vault protein and
  - (b) an instruction for diagnosing, or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or determining the propensity or predisposition of a subject to develop such a disease by (i) detecting a level, or an activity, or both said level and said activity, of said transcription product and/or said

translation product of a gene coding for a vault protein, in a sample from said subject; and (ii) diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or determining the propensity or predisposition of said subject to develop such a disease, wherein a varied level, or activity, or both said level and said activity, of said transcription product and/or said translation product compared to a reference value representing a known health status; or a level, or activity, or both said level and said activity, of said transcription product and/or said translation product similar or equal to a reference value representing a known disease status indicates a diagnosis or prognosis of a neurodegenerative disease, in particular Alzheimer's disease, or an increased propensity or predisposition of developing such a disease.

10.A method of treating or preventing a neurodegenerative disease, in particular AD, in a subject comprising administering to said subject in a therapeutically or prophylactically effective amount an agent or agents which directly or indirectly affect an activity and/or a level of

- (i) a gene coding for a vault protein, and/or
- (ii) a transcription product of a gene coding for a vault protein, and/or
- (iii) a translation product of a gene coding for a vault protein, and/or
- (iv) a fragment, or derivative, or variant of (i) to (iii).

11.A modulator of an activity and/or of a level of at least one substance which is selected from the group consisting of

- (i) a gene coding for a vault protein and/or
- (ii) a transcription product of a gene coding for a vault protein and/or
- (iii) a translation product of a gene coding for a vault protein, and/or
- (iv) a fragment, or derivative, or variant of (i) to (iii).

12.A recombinant, non-human animal comprising a non-native gene sequence coding for a vault protein or a fragment, or a derivative, or a variant thereof, said animal being obtainable by:

- (i) providing a gene targeting construct comprising said gene sequence and a selectable marker sequence, and
- (ii) introducing said targeting construct into a stem cell of a non-human animal, and
- (iii) introducing said non-human animal stem cell into a non-human embryo, and

- (iv) transplanting said embryo into a pseudopregnant non-human animal, and
- (v) allowing said embryo to develop to term, and
- (vi) identifying a genetically altered non-human animal whose genome comprises a modification of said gene sequence in both alleles, and
- (vii) breeding the genetically altered non-human animal of step (vi) to obtain a genetically altered non-human animal whose genome comprises a modification of said endogenous gene, wherein said disruption results in said non-human animal exhibiting a predisposition to developing symptoms of a neurodegenerative disease or related diseases or disorders.

13. The animal according to claim 12 wherein said vault protein is a minor vault protein, in particular the minor vault protein ADPRTL1, SEQ ID NO.2.

14. Use of the recombinant, non-human animal according to claim 12 or 13 for screening, testing, and validating compounds, agents, and modulators in the development of diagnostics and therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease.

15. An assay for screening for a modulator of neurodegenerative diseases, in particular Alzheimer's disease, or related diseases or disorders of one or more substances selected from the group consisting of

- (i) a gene coding for a vault protein, and/or
- (ii) a transcription product of a gene coding for a vault protein, and/or
- (iii) a translation product of a gene coding for a vault protein, and/or
- (iv) a fragment, or derivative, or variant of (i) to (iii),

said method comprising:

- (a) contacting a cell with a test compound;
- (b) measuring the activity and/or level of one or more substances recited in (i) to (iv);
- (c) measuring the activity and/or level of one or more substances recited in (i) to (iv) in a control cell not contacted with said test compound; and
- (d) comparing the levels and/or activities of the substance in the cells of step (b) and (c), wherein an alteration in the activity and/or level of substances in the contacted cells indicates that the test compound is a modulator of said diseases or disorders.

16. A method of screening for a modulator of neurodegenerative diseases, in particular Alzheimer's disease, or related diseases or disorders of one or more substances selected from the group consisting of

- (i) a gene coding for a vault protein, and/or
- (ii) a transcription product of a gene coding for a vault protein, and/or
- (iii) a translation product of a gene coding for a vault protein, and/or
- (v) a fragment, or derivative, or variant of (i) to (iii),

said method comprising:

- (a) administering a test compound to a test animal which is predisposed to developing or has already developed symptoms of a neurodegenerative disease or related diseases or disorders in respect of the substances recited in (i) to (iv);
- (b) measuring the activity and/or level of one or more substances recited in (i) to (iv);
- (c) measuring the activity and/or level of one or more substances recited in (i) or (iv) in a matched control animal which is predisposed to developing or has already developed symptoms of a neurodegenerative disease or related diseases or disorders in respect to the substances recited in (i) to (iv) and to which animal no such test compound has been administered;
- (d) comparing the activity and/or level of the substance in the animals of step (b) and (c), wherein an alteration in the activity and/or level of substances in the test animal indicates that the test compound is a modulator of said diseases or disorders.

17. The method according to claim 16 wherein said test animal and/or said control animal is a recombinant animal which expresses a vault protein, or a fragment, or a derivative, or a variant thereof, under the control of a transcriptional control element which is not the native vault protein gene transcriptional control element.

18. An assay for testing a compound, preferably for screening a plurality of compounds for inhibition of binding between a ligand and a vault protein, or a fragment, or derivative, or a variant thereof, said assay comprising the steps of:

- (i) adding a liquid suspension of said vault protein, or a fragment, or a derivative, or a variant thereof, to a plurality of containers;
- (ii) adding a compound, preferably a plurality of compounds, to be screened for said inhibition of binding to said plurality of containers;

- (iii) adding a detectable ligand, in particular a fluorescently detectable ligand, to said containers;
- (iv) incubating the liquid suspension of said vault protein, or said fragment, or derivative, or variant thereof, and said compound, preferably said plurality of compounds, and said ligand;
- (v) measuring amounts of detectable ligand or fluorescence associated with said vault protein, or with said fragment, or derivative, or variant thereof; and
- (vi) determining the degree of inhibition by one or more of said compounds of binding of said ligand to said vault protein, or said fragment, or derivative, or variant thereof.

19. An assay for testing a compound, preferably for screening a plurality of compounds to determine the degree of binding of said compounds to a vault protein, or to a fragment, or derivative, or variant thereof, said assay comprising the steps of:

- (i) adding a liquid suspension of said vault protein, or a fragment, or derivative, or variant thereof, to a plurality of containers;
- (ii) adding a detectable compound, preferably a plurality of detectable compounds, in particular fluorescently detectable compounds, to be screened for said binding to said plurality of containers;
- (iii) incubating the liquid suspension of said vault protein, or said fragment, or derivative, or variant thereof, and said compound, preferably said plurality of compounds;
- (iv) measuring amounts of detectable compound or fluorescence associated with said vault protein, or with said fragment, or derivative, or variant thereof; and
- (v) determining the degree of binding by one or more of said compounds to said vault protein, or said fragment, or derivative, or variant thereof.

20. A protein molecule, said protein molecule being a translation product of the gene coding for a vault protein, in particular the minor vault protein ADPRTL1, SEQ ID NO. 2, or a fragment, or derivative, or variant thereof, for use as a diagnostic target for detecting a neurodegenerative disease, preferably Alzheimer's disease.


21. A protein molecule, said protein molecule being a translation product of the gene coding for a vault protein, in particular the minor vault protein ADPRTL1, SEQ ID NO. 2, or a fragment, or derivative, or variant thereof, for use as a screening

REPLACED BY  
ART 34 AMDT

target for reagents or compounds preventing, or treating, or ameliorating a neurodegenerative disease, preferably Alzheimer's disease.


22. Use of an antibody specifically immunoreactive with an immunogen, wherein said immunogen is a translation product of a gene coding for a vault protein, in particular the minor vault protein ADPRTL1, SEQ ID NO. 2, or a fragment, or derivative, or variant thereof, for detecting the pathological state of a cell in a sample from a subject, comprising immunocytochemical staining of said cell with said antibody, wherein an altered degree of staining, or an altered staining pattern in said cell compared to a cell representing a known health status indicates a pathological state of said cell, and wherein said pathological state relates to a neurodegenerative disease, in particular Alzheimer's disease.

**Fig. 1: Identification of genes involved in Alzheimer's Disease pathology**







**Fig. 2: Identification of differentially expressed  
Alzheimer's disease genes in a fluorescence  
differential display screen**



**Fig. 3: Verification of differential expression of the minor vault protein ADPRTL1 gene by quantitative PCR**



**Fig. 4: Verification of differential expression of the minor vault protein ADPRTL1 gene by quantitative PCR**




## Figure 5: Nucleotide sequence of SEQ ID NO. 1

Length: 35 bp

1 AATCTAGGAA TATTCCTGG GCTTTTGAGG CAATC

**Fig. 6: Schematic alignment of SEQ ID NO. 1  
with minor vault protein ADPRTL1 cDNA  
(GenBank accession number AF057160)**



**Fig. 7: Alignment of SEQ ID NO.1 with minor vault protein ADPRTL1 cDNA (AF057160)**

1 TCTAGGAATATTCCCTGGGCTTTTGAGGCAAT 33  
 || |||||  
 5027 TCCAGGAATATTCCCTGGGCTTTTGAGGCAAT 5058

**Fig. 8: SEQ ID NO. 2: amino acid sequence of human minor vault protein ADPRTL1**

**Length: 1724 aa**

1	MVMGIFANCI	FCLKVKYLPQ	QQKKKLQTDI	KENGGKFSFS	LNPQCTHIIL
51	DNADVLSQYQ	LNSIQKNHVH	IANPDFIWKS	IREKRLLDVK	NYDPYKPLDI
101	TPPPDQKASS	SEVKTEGLCP	DSATEEEDTV	ELTEFGMQNV	EIPHL PQDFE
151	VAKYNTLEKV	GMEGGQEAVV	VELQCSRDSR	DCPFLISSHF	LLDDGMETR
201	QFAIKKTS	ASEYFENYIE	ELKKQGFLLR	EHFTPEATQL	ASEQLQALLL
251	EEVMNSSTLS	QEVSDLVEMI	WAEALGHLEH	MLLKPVNRIS	LNDVSKAEGI
301	LLL VKAALKN	GETAEQLQKM	MTEFYRLIPH	KGTMPKEVNL	GLLAKKADLC
351	QLIRDMVNVC	ETNLSKPNPP	SLAKYRALRC	KIEHVEQNT	EFLRVRKEVL
401	QNHHSKSPVD	VLQIFRVGRV	NETTEFLSKL	GNVRPLLHGS	PVQNI VGILC
451	RGLLLPKVVE	DRGVQRTDVG	NLGSGIYFSD	SLSTSIKYSH	PGETDGTRLL
501	LICDVALGKC	MDLHEKD FSL	TEAPPGYDSV	HGVSQTASVT	TDFEDDEFVV
551	YKTNQVKMKY	IIKFSPMGDQ	IKDFHPSDHT	ELEEYRPEFS	NFSKVEDYQL
601	PDAKTSSTK	AGLQDASGNL	VPLEDVHIKG	RIIDTVAQVI	VFQTYTNKSH
651	VPIEAKYIFP	LDDKAAVCGF	EAFINGK HIV	GEIKEKEEAQ	QEYLEAVTQG
701	HGAYLMSQDA	PDVFTVSVGN	LPPKAKVLIK	ITYITEL SIL	GTVG VFFMPA
751	TVAPWQQDKA	LNENLQDTVE	KICIKEIGTK	QSFSLTMSIE	MPYVIEFIFS
801	DTHELKQKRT	DCKAVISTME	GSSLDSSGFS	LHIGLSAAYL	PRMWVEKHPE
851	KESEACMLVF	QPDLDVDLPD	LASESEVIIC	LDCSSSMEGV	TFLQAKQIAL
901	HALSLVGEKQ	KVNIIQFGTG	YKELFSYPKH	ITSNTAAAEF	IMSATPTMGN
951	TDFWKTLRYL	SLLYPARGSR	NILLVSDGHL	QDESLTLQLV	KRSRP HTRLF
1001	ACGIGSTANR	HVLRILSQCG	AGVFEYFNAK	SKHSWRKQIE	DQMTRLCSPS
1051	CHSVSVKWQQ	LNPDAPEALQ	APAQVPSLFR	NDRLLVYGFI	PHCTQATLCA
1101	LIQEKEFCTM	VSTTELQKTT	GTMIHKLAAR	ALIRDYEDGI	LHENETSHEM
1151	KKQTLKSLII	KLSKENS LIT	QFTSFVAVEK	RDENESFPFD	IPKVSELI AK
1201	EDVDFLPYMS	WQGE PQEAVR	NQSLLASSEW	PELRLSKRKH	RKIPFSKRKM
1251	ELS QPEVSED	FEEDGLGVLP	AFTSNLERGG	VEKL DLSWT	ESCKPTATEP
1301	LFKKVSPWET	STSSFFPILA	PAVGSYLTPT	TRAHSPASLS	FASYRQVASF
1351	GSAAPPRQFD	ASQFSQGPVP	GT CADWIPQS	ASCPTGPPQN	PPSAPYCGIV
1401	FSGSSLSSAQ	SAPLQH PGGF	TTRPSAGTFP	ELDSPQLHFS	LPTDPDPIRG
1451	FGSYHPSAYS	PFHFQPSAAS	LTANLRLPMA	SALPEALCSQ	SRTTPVDLCL
1501	LEESVGSLEG	SRCPVFAFQS	SDTESDELSE	VLQDSCFLQI	KCDTKD DSIP
1551	CFLEVKEEDE	IVCTQHWQDA	VPWTELLSLQ	TEDGFWKLT	ELGLILNLNT
1601	NGLHSFLKQK	GIQSLGVKGR	ECLLDLIATM	LVLQFIRTRL	EKEGIVFKSL
1651	MKMDDP SISR	NIPWAF EAIK	QASEWVR RTE	GQYPSICPRL	ELGNDWDSAT
1701	KQLLGLQ PIS	TVSPLHRVLH	YSQG		

**Fig. 9: Images of the human cerebral cortex  
labeled with anti-ADPRTL1 monoclonal  
antibody and with DAPI**






Table 1 :

sample  $\Delta$  (fold)  
(temporal / frontal cortex)

control C011	0.77
control C012	0.98
control C014	0.93
control C005	1.02
control C008	1.23
patient P012	0.91
patient P016	1.62
patient P010	0.91
patient P011	1.69
patient P014	1.33
patient P017	1.53
patient P019	1.55





Table 2:

sample  $\Delta$  (fold)  
(hippocampus / frontal cortex)

control C005	1.28
control C008	1.57
control C004	1.86
patient P012	1.40
patient P016	2.11
patient P010	1.32
patient P011	1.51
patient P014	1.24
patient P019	1.93



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
16 October 2003 (16.10.2003)

PCT

(10) International Publication Number  
WO 2003/085131 A3

(51) International Patent Classification<sup>7</sup>: C12Q 1/68,  
C12N 9/10, G01N 33/53, A01K 67/027, A61P 25/00

(74) Agents: MEYERS, Hans-Wilhelm et al.; Postfach 10 22  
41, 50462 Köln (DE).

(21) International Application Number:  
PCT/EP2003/003626

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 8 April 2003 (08.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02007820.0 8 April 2002 (08.04.2002) EP  
60/370,214 8 April 2002 (08.04.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,  
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): EVOTEC  
NEUROSCIENCES GMBH [DE/DE]; Schnackenburg-  
allee 114, 22525 Hamburg (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): VON DER KAM-  
MER, Heinz [DE/DE]; Verbindungsstr. 6d, 22607 Ham-  
burg (DE). POHLNER, Johannes [DE/DE]; Quittenweg  
11, 22175 Hamburg (DE).

Published:


— with international search report

(88) Date of publication of the international search report:  
2 September 2004

[Continued on next page]

(54) Title: DIAGNOSTIC AND THERAPEUTIC USE OF VAULT POLYNUCLEOTIDES AND PROTEINS FOR NEURODE-  
GENERATIVE DISEASES

# Identification of differentially expressed Alzheimer's disease genes in a fluorescence differential display screen



(57) Abstract: The present invention discloses the differential expression of the minor vault protein ADPRTL gene in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating Alzheimer's disease in a subject, or for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using a gene coding for a vault protein, in particular the gene coding for the minor vault protein ADPRTL1. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

WO 2003/085131 A3

**WO 2003/085131 A3**



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/03626

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 C12N9/10 G01N33/53 A01K67/027 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, MEDLINE, Sequence Search

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KIRCKHOEFER V A ET AL: "The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase" THE JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, US, vol. 146, no. 5, 6 September 1999 (1999-09-06), pages 917-928, XP002180527 ISSN: 0021-9525 cited in the application	9,20,21
Y	the whole document  ----- -/--	1-8, 12-17,22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 October 2003

Date of mailing of the international search report

27.01.2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hagenmaier, S

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/03626

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STILL I H ET AL: "Identification of a novel gene (ADPRTL1) encoding a potential Poly(ADP-ribosyl)transferase protein." GENOMICS. UNITED STATES 15 DEC 1999, vol. 62, no. 3, 15 December 1999 (1999-12-15), pages 533-536, XP002233085 ISSN: 0888-7543 cited in the application	9,20,21
Y	the whole document	1-8, 12-17,22
X	----- WO 99/62547 A (ROME LEONARD H ;UNIV CALIFORNIA (US); KICKHOEFER VALERIE A (US)) 9 December 1999 (1999-12-09) cited in the application	9,20,21
Y	the whole document	1-8, 12-17,22
Y	----- CHIARUGI A: "Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 3, 1 March 2002 (2002-03-01), pages 122-129, XP004339352 ISSN: 0165-6147 cited in the application	1-9, 12-17,22
Y	the whole document	
Y	----- SMITH S: "The world according to PARP" TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 26, no. 3, 1 March 2001 (2001-03-01), pages 174-179, XP004229459 ISSN: 0968-0004 the whole document	1-9, 12-17,22
Y	----- LOVE S ET AL: "Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease." BRAIN;A JOURNAL OF NEUROLOGY. ENGLAND FEB 1999, vol. 122 ( Pt 2), February 1999 (1999-02), pages 247-253, XP002233086 ISSN: 0006-8950 the whole document	1-9, 12-17,22
Y	----- WO 02/22792 A (LUESCHER BERNHARD ;AUSTEN MATTHIAS (US)) 21 March 2002 (2002-03-21) see pages 1-3; claims the whole document	1-9, 12-17,22
	----- -/--	

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/03626

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>PERKINS E ET AL: "NOVEL INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE/PARP1 A. PARP2 IDENTIFIED USING A CELL-BASED SCREEN IN YEAST"</p> <p>CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 10, 15 May 2001 (2001-05-15), pages 4175-4183, XP002208915 ISSN: 0008-5472 the whole document</p>	1-9, 12-17,22
A	<p>EP 1 188 839 A (EVOTEC NEUROSCIENCES GMBH) 20 March 2002 (2002-03-20) the whole document</p>	
A	<p>WO 02/16636 A (EVOTEC NEUROSCIENCES GMBH ;HIPFEL RAINER (DE); KRAPPA RALF (DE); P) 28 February 2002 (2002-02-28) the whole document</p>	
A	<p>LORING J F ET AL: "A gene expression profile of Alzheimer's disease." DNA AND CELL BIOLOGY. UNITED STATES NOV 2001, vol. 20, no. 11, November 2001 (2001-11), pages 683-695, XP002233087 ISSN: 1044-5498 the whole document</p>	
A	<p>"Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group." NEUROBIOLOGY OF AGING. UNITED STATES 1998 MAR-APR, vol. 19, no. 2, March 1998 (1998-03), pages 109-116, XP002233088 ISSN: 0197-4580 the whole document</p>	
A	<p>WO 99/11649 A (GUILFORD PHARM INC) 11 March 1999 (1999-03-11) the whole document</p>	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/03626

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9962547	A	09-12-1999	WO 9962547 A1	09-12-1999
			AU 762371 B2	26-06-2003
			AU 7810398 A	20-12-1999
			CA 2330833 A1	09-12-1999
			EP 1083927 A1	21-03-2001
			JP 2002516675 T	11-06-2002
WO 0222792	A	21-03-2002	AU 2054602 A	26-03-2002
			WO 0222792 A2	21-03-2002
EP 1188839	A	20-03-2002	EP 1188839 A1	20-03-2002
WO 0216636	A	28-02-2002	AU 8983401 A	04-03-2002
			WO 0216636 A2	28-02-2002
			EP 1377678 A2	07-01-2004
WO 9911649	A	11-03-1999	US 6346536 B1	12-02-2002
			US 6635642 B1	21-10-2003
			<del>AU 9297898 A</del>	<del>22-03-1999</del>
			AU 9298098 A	22-03-1999
			AU 9298198 A	22-03-1999
			AU 9298698 A	22-03-1999
			AU 752768 B2	26-09-2002
			AU 9299198 A	22-03-1999
			AU 9374898 A	22-03-1999
			BR 9812428 A	26-09-2000
			CN 1278797 T	03-01-2001
			EP 1009739 A2	21-06-2000
			EP 1012145 A1	28-06-2000
			EP 1012153 A1	28-06-2000
			HU 0004693 A2	28-10-2001
			JP 2002515072 T	21-05-2002
			JP 2002512637 T	23-04-2002
			JP 2002511888 T	16-04-2002
			NO 20001002 A	27-04-2000
			PL 339082 A1	04-12-2000
			TR 200001557 T2	22-01-2001
			US 6426415 B1	30-07-2002
			WO 9911623 A1	11-03-1999
			WO 9911649 A2	11-03-1999
			WO 9911622 A1	11-03-1999
			WO 9911644 A1	11-03-1999
			WO 9911624 A1	11-03-1999
			WO 9911628 A1	11-03-1999
			US 2003105102 A1	05-06-2003
			US 6197785 B1	06-03-2001
			US 2002028813 A1	07-03-2002
			US 2002022636 A1	21-02-2002
			US 6121278 A	19-09-2000
			US 6235748 B1	22-05-2001
			US 6380211 B1	30-04-2002
			ZA 9808010 A	03-03-1999
			ZA 9808011 A	03-03-1999
			ZA 9808012 A	03-03-1999
			ZA 9808013 A	03-03-1999
			ZA 9808015 A	03-03-1999
			AU 9298298 A	22-03-1999
			BR 9812185 A	18-07-2000



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 03/03626

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 10  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☒ Claims Nos.: 11  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
~~because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).~~

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-17, 20-22 (all completely)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 10

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

-----

Continuation of Box I.2

Claims Nos.: 11

Present claim 11 relates to a product defined by reference to a desirable characteristic or property, namely being a modulator of an activity or a level of at least one substance selected from the group listed in claim 11 under (i)-(iv). The claim covers all products having this characteristic or property, whereas the application does not provide any support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for such products. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search is impossible. Independent of the above reasoning, the claim also lacks clarity (Article 6 PCT). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search impossible. Consequently, no search has been carried out for claim 11.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-17,20-22 (all completely)

Methods of diagnosing, prognosticating, monitoring the progression or evaluating a treatment of a neurodegenerative disease comprising determining the level and/or activity of a transcription/translation product of a gene coding for a vault protein in a sample; a kit for diagnosing or prognosticating a neurodegenerative disease comprising at least one reagent that selectively detects a transcription/translation product of a gene coding for a vault protein; a recombinant non-human animal comprising a ~~non-native gene sequence of a vault protein, an assay for~~ screening for a modulator of a neurodegenerative disease using vault polynucleotides or proteins, a protein molecule being a translation product of the gene coding for a vault protein for use as a diagnostic/screening target for a neurodegenerative disease, use of an antibody specifically immunoreactive with an immunogen, wherein said immunogen is a translation product of a gene coding for a vault protein for detecting a neurodegenerative disease.

---

2. claims: 18,19 (all completely)

An assay for testing a compound, preferably for screening a plurality of compounds for inhibition of binding between a ligand and a vault protein and an assay for testing a compound, preferably for screening a plurality of compounds to determine the degree of binding of said compounds to a vault protein.

---

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/03626

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9911649	A	CN 1277613 T	20-12-2000
		EP 1019409 A1	19-07-2000
		HU 0003569 A2	30-07-2001
		JP 2002510332 T	02-04-2002
		NO 20001001 A	05-04-2000
		NZ 503043 A	25-10-2002
		PL 338950 A1	04-12-2000
-----			

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**